RANI (ranitherapeutics.com) Dhuwit awis perusahaan

Logo grafis Rani Therapeutics (RANI)

Rani Therapeutics relies on funding for clinical trials of its robotic capsules. The business model is independent of economic cycles or GDP, as biotech success is driven by medical breakthroughs. The remaining cash balance confirms this status, where the amount of 0.04 serves as a financial shield. Growth in the company's valuation is currently driven by agreements to implement RaniPill technology as a replacement for injections.

RANI - Sisa dhuwit perusahaan Rani Therapeutics ing rentang 04.07.2022 - 21.11.2026

Rincian metrik keuangan lan pasar Rani Therapeutics (RANI)

Analisis komprehensif perusahaan:RANI Rani Therapeutics Holdings
Produk mawa merek Rani Therapeutics Inc

This indicator measures the volume of liquid assets, determining the business's ability to maintain operations and avoid default in the absence of external financing. By analyzing the cash balance, an investor assesses the financial cushion of Rani Therapeutics (RANI), which is critical for covering high R&D costs and the development of injectable capsules prior to achieving clinical success.

Analisis pesaing Rani Therapeutics

Dana dhuwit perusahaan Haleon (HLN)|Volume dana dhuwit perusahaan Kenvue Inc. (KVUE)|Volume dana dhuwit perusahaan VRNA (veronapharma.com)|Sisa dhuwit perusahaan MENS|LGND: Dhuwit awis perusahaan|Sisa dhuwit perusahaan AMRX (Amneal Corp)|PRGO (Perrigo Company plc) - Dhuwit awis perusahaan|Alvotech - Sisa dhuwit perusahaan|Dhuwit awis perusahaan LQDA|Galapagos Genomics (GLPG) - Aset likuid perusahaan|Volume dana dhuwit perusahaan ANIP|Dhuwit awis perusahaan Afrezza MNKD|Dana dhuwit perusahaan Amphastar AMPH|Aset likuid perusahaan Pacira BioSciences (PCRX)|ARS Corp - Volume dana dhuwit perusahaan|TBPH: Dana dhuwit perusahaan|AQST: Volume dana dhuwit perusahaan|SCPH - Aset likuid perusahaan|TECX (Tectonic) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Tonix Pharmaceuticals Holding Corp. TNXP|Dana dhuwit perusahaan SXT Pharmaceuticals (SXTC)|Volume dana dhuwit perusahaan Eupraxia Pharmaceuticals Inc. (EPRX)|Dana dhuwit perusahaan BioHarvest Sciences BHST|EXOZ (Invizyne) - Total volume dana dhuwit perusahaan|ORMP: Dhuwit awis perusahaan|ENTX (Entera Bio Ltd) - Dhuwit awis lan setara dhuwit awis perusahaan|HYFT: Volume dana dhuwit perusahaan|Dhuwit awis perusahaan ABVC BioPharma Inc.|CPIX (cumberlandpharma.com) - Volume dana dhuwit perusahaan|Dana dhuwit perusahaan QNTM|Volume dana dhuwit perusahaan FGEN|Dhuwit awis perusahaan Telomir Pharmaceuticals TELO|Dana dhuwit perusahaan Synergy CHC Corp. SNYR|Sisa dhuwit perusahaan RLYB|LEXX: Dhuwit awis perusahaan|Sisa dhuwit perusahaan PULM (Pulmatrix Corporation)|Pheton Holdings Limited (PTHL) - Dana dhuwit perusahaan|Dhuwit awis perusahaan Aptorum|Dhuwit awis perusahaan LYRA|Impact BioMedical Inc - Total volume dana dhuwit perusahaan|Volume dana dhuwit perusahaan TNFA|YCBD - Cadangan dhuwit perusahaan|PainReform Ltd. - Dhuwit awis perusahaan|CYTO (Auris Medical) - Total volume dana dhuwit perusahaan|LIPO - Dana dhuwit perusahaan|Sisa dhuwit perusahaan OPTN (OptiNose)|PIRS: Volume dana dhuwit perusahaan|Procaps Group S.A. (PROC) - Volume dana dhuwit perusahaan|PTPI (Petros Pharma) - Volume dana dhuwit perusahaan|QLI: Sisa dhuwit perusahaan|Volume dana dhuwit perusahaan SLRN|TFFP (TFF Pharmaceuticals Inc.) - Sisa dhuwit perusahaan